Modality
Cell Therapy
MOA
CDK4/6i
Target
DLL3
Pathway
PI3K/AKT
Psoriasis
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Jun 2030
Phase 2Current
NCT06675278
2,203 pts·Psoriasis
2023-02→2030-06·Not yet recruiting
2,203 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-094.2y awayPh2 Data· Psoriasis
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Not yet…
Catalysts
Ph2 Data
2030-06-09 · 4.2y away
Psoriasis
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06675278 | Phase 2 | Psoriasis | Not yet recr... | 2203 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |